Elmind Capital LP Invests $18.18 Million in Pharvaris N.V. $PHVS

Elmind Capital LP acquired a new stake in shares of Pharvaris N.V. (NASDAQ:PHVS - Free Report) in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund acquired 525,750 shares of the company's stock, valued at approximately $18,180,435. Pharvaris accounts for about 0.0% of Elmind Capital LP's investment portfolio, making the stock its 7th biggest holding. Elmind Capital LP owned approximately 0.80% of Pharvaris at the end of the most recent reporting period.

A number of other institutional investors have also recently added to or reduced their stakes in the business. venBio Partners LLC raised its stake in shares of Pharvaris by 8.2% in the third quarter. venBio Partners LLC now owns 4,639,304 shares of the company's stock worth $115,751,000 after acquiring an additional 350,000 shares during the last quarter. Deerfield Management Company L.P. grew its holdings in shares of Pharvaris by 21.1% in the third quarter. Deerfield Management Company L.P. now owns 2,442,464 shares of the company's stock valued at $60,939,000 after acquiring an additional 425,000 shares in the last quarter. Commodore Capital LP grew its stake in Pharvaris by 1.6% during the first quarter. Commodore Capital LP now owns 1,918,970 shares of the company's stock valued at $54,211,000 after acquiring an additional 29,525 shares in the last quarter. Paradigm Biocapital Advisors LP increased its stake in Pharvaris by 72.7% in the 3rd quarter. Paradigm Biocapital Advisors LP now owns 1,835,494 shares of the company's stock worth $45,796,000 after purchasing an additional 772,583 shares during the period. Finally, Wellington Management Group LLP purchased a new stake in Pharvaris in the third quarter worth about $43,282,000.

Wall Street Analyst Weigh In

Several brokerages have recently weighed in on PHVS. Citizens Jmp increased their price target on Pharvaris from $74.00 to $75.00 and gave the stock a "market outperform" rating in a report on Thursday, August 13th. UBS Group set a $74.00 price objective on Pharvaris in a report on Wednesday, May 13th. Citigroup reaffirmed a "market outperform" rating on shares of Pharvaris in a report on Thursday, August 13th. Royal Bank Of Canada upped their target price on Pharvaris from $51.00 to $52.00 and gave the stock an "outperform" rating in a research report on Thursday, August 13th. Finally, Wells Fargo & Company began coverage on shares of Pharvaris in a research note on Wednesday, July 15th. They issued an "overweight" rating and a $55.00 target price for the company. One research analyst has rated the stock with a Strong Buy rating, eleven have assigned a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company's stock. According to MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and an average target price of $51.08.

Insider Transactions at Pharvaris

In related news, insider Anne Lesage sold 30,703 shares of the stock in a transaction dated Tuesday, June 30th. The shares were sold at an average price of $35.49, for a total value of $1,089,649.47. Following the completion of the transaction, the insider owned 93,969 shares in the company, valued at $3,334,959.81. This represents a 24.63% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. Also, insider Anna Nijdam sold 2,670 shares of the firm's stock in a transaction that occurred on Thursday, June 4th. The shares were sold at an average price of $30.87, for a total value of $82,422.90. Following the completion of the transaction, the insider directly owned 46,275 shares in the company, valued at $1,428,509.25. The trade was a 5.46% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last 90 days, insiders sold 121,325 shares of company stock worth $4,270,425. 11.84% of the stock is currently owned by corporate insiders.

Pharvaris Stock Performance

Shares of NASDAQ PHVS traded down $1.42 during midday trading on Friday, reaching $35.58. The stock had a trading volume of 383,686 shares, compared to its average volume of 336,819. Pharvaris N.V. has a 12-month low of $20.65 and a 12-month high of $38.13. The stock has a 50-day moving average of $34.56 and a 200-day moving average of $30.71. The company has a market capitalization of $2.33 billion, a price-to-earnings ratio of -11.67 and a beta of -2.31.

Pharvaris (NASDAQ:PHVS - Get Free Report) last announced its quarterly earnings results on Wednesday, August 12th. The company reported ($0.81) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.75) by ($0.06). As a group, analysts forecast that Pharvaris N.V. will post -3.15 EPS for the current fiscal year.

Pharvaris Profile

Pharvaris is a clinical-stage biopharmaceutical company focused on discovering and developing novel oral therapies for rare bradykinin-driven diseases. The company's core mission is to address conditions characterized by uncontrolled activation of the plasma kallikrein-kinin system, with a primary emphasis on hereditary angioedema (HAE), a debilitating disorder marked by recurrent swelling episodes.

The company's lead program, PHA121, is an investigational once-daily oral plasma kallikrein inhibitor designed for prophylactic treatment of HAE and is advancing through clinical trials.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source